Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Jan-Dec:30:10760296241261364.
doi: 10.1177/10760296241261364.

Efficacy and Safety of Rivaroxaban Versus Enoxaparin in Prevention of Recurrence of Venous Thrombo-Embolism Events in Cancer Patients: A Meta-Analysis

Abdul Rafeh Awan  1 , Abdullah Ahmad  2 , Muhammad Daniyal  2 , Malik Muhammad Hamza Khan  3 , Shaikh Jehanzaib Saeed  3 , Muhammad Bilal Siddiqui  3 , Sheraz Hakeem  3 , Azka Shahab  4 , Syed Hasham Ali  5 , Ahmed Kamal Siddiqi  6
Affiliations
Review

Efficacy and Safety of Rivaroxaban Versus Enoxaparin in Prevention of Recurrence of Venous Thrombo-Embolism Events in Cancer Patients: A Meta-Analysis

Abdul Rafeh Awan et al. Clin Appl Thromb Hemost. 2024 Jan-Dec.

Abstract

Objective: To examine the effectiveness of rivaroxaban compared to enoxaparin in patients diagnosed with cancer and venous thromboembolism.

Methods: A search of Pub Med, Scopus, and Google Scholar, from inception through April 2023 was conducted. Articles comparing rivaroxaban with enoxaparin in patients with cancer and VTE/PE/DVT were included. Review Manager Version 5.2 was utilised for the analysis of the following outcomes; VTE, PE, DVT, major bleeding, and mortality.

Results: A total of 8 articles and 2276 patients were included in the final analysis. Pooled analysis showed that rivaroxaban had a statistically insignificant reduced association with VTE occurrence (RR:0.83, 95% CI:0.58-1.18, P:0.3) as well as a statically insignificant reduction in major bleeding (RR:0.79, 95% CI:0.53-1.18, P:0.25). Analysis showcased that there was an insignificant reduction of mortality rivaroxaban as compared to enoxaparin (RR:0.74, 95% CI: 0.46-1.20, P:0.23).

Conclusion: Rivaroxaban can serve as a viable alternative to enoxaparin, with no appreciable drawbacks, for preventing and managing VTE in patients with malignancy.

Keywords: cancer; chemotherapy; enoxaparin; low molecular weight heparin; rivaroxaban; venous thromboembolism.

PubMed Disclaimer

Conflict of interest statement

Declaration of Conflicting InterestsThe authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Figures

Figure 1.
Figure 1.
PRISMA flow diagram.
Figure 2.
Figure 2.
Forest plot for recurrence of VTE.
Figure 3.
Figure 3.
Forest plot for recurrence of DVT.
Figure 4.
Figure 4.
Forest plot for recurrence of PE.
Figure 5.
Figure 5.
Forest plot for Mortality.
Figure 6.
Figure 6.
Forest plot for Major bleeding.
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Silverstein MD, H eit JA, Mohr DN, Petterson TM, O’Fallon WM, Melton LJ. Trends in the incidence of deep vein thrombosis and pulmonary embolism. Arch Intern Med. 1998;158(6):585. - PubMed
    1. Büller HR, Davidson BL, Decousus H, et al. Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism. N Engl J Med. 2003;349(18):1695-1702. - PubMed
    1. Streiff MB, Holmstrom B, Ashrani A, et al. Cancer-Associated venous thromboembolic disease, version 1.2015. J Natl Compr Canc Netw. 2015;13(9):1079-1095. - PubMed
    1. Lee AYY, Levine MN, Baker RI, et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med. 2003;349(2):146-153. - PubMed
    1. Nunnelee JD. Review of an article: Oral rivaroxaban for symptomatic venous thromboembolism. The EINSTEIN investigators et al. N Engl J Med 2010; 363(26):2499-2510. J Vasc Nurs. 2011;29(2):89. - PubMed

MeSH terms